Kinevant Sciences (kine-a-vant) is developing new therapies for rare inflammatory and autoimmune diseases, initially focusing on sarcoidosis with an anti-GM-CSF monoclonal antibody (namilumab).
Kinevant’s lead investigational product candidate, namilumab*, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor (GM-CSF), a key pro-inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
*Namilumab is not approved in any market.
We are innovators focused on creating value for patients by applying our considerable resources and clinical expertise to the development of new therapies for the treatment of serious inflammatory and autoimmune diseases.
If you have a track-record of success and progression in your career, are mission oriented, and motivated by the potential to solve intractable diseases, please consider joining us at Kinevant.